Recent

% | $
Quotes you view appear here for quick access.

Omeros Corporation (OMER) Message Board

dooper55 36 posts  |  Last Activity: 12 hours ago Member since: Dec 9, 2006
  • Reply to

    Pros and cons of Omidria

    by dooper55 Apr 23, 2015 12:07 PM
    dooper55 dooper55 12 hours ago Flag

    The link is easy to get to ....... trustintelligence (+ (phonetic) daht kahm)

    Click on "Trust Intelligence Discussion Forums"

    Click on "BIOTECH: PROVECTUS (PVCT) + OMEROS (OMER) + more" toward bottom, under "Forum"

    Click on "Omeros Corporation (OMER)"

    Post #5 has the pros/cons

  • Alan Ross discusses this topic and provides links to articles in post #5 on the Omeros thread at TrustIntelligence daht kahm. It'll be interesting to see if that phonetic version of a link works. :-)

  • Prescient Investment Analysis
    Disclosure: The author is long OMER.

    Value, growth at reasonable price, event-driven

    Omeros Corporation's Omidria Has Hallmarks Of Success

    Apr. 16, 2015 2:31 PM ET

    Summary
    •There are multiple reasons that Omidria can be successful.
    •Safety, ease of access, reduced stress on surgeons, and reimbursement are among them.
    •The product's value appears substantial to investors.

  • dooper55 by dooper55 Apr 15, 2015 4:34 PM Flag

    Provectus Biopharmaceuticals Opens Patient Enrollment; Begins Phase 3 International FDA Comparative Clinical Trial of PV-10 for Melanoma

    Interim Data Expected When 50% of Events Achieved

    Wednesday April 15, 2015

    KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus"), enters phase 3 and has opened enrollment of patients for its phase 3 international FDA comparative clinical trial of PV-10 for melanoma. The Company is seeking 225 patients and enrollment has begun at St. Luke's University Hospital and Health Network, Bethlehem, PA, the first study site to be opened, with additional sites to be added in the coming weeks and months.

  • "Compassionate Use Approval Provides Glimpse of Trial Efficacy"

    The article is available at the Trust Intelligence Forum.

  • Reply to

    At least the presentation materials are available

    by dooper55 Apr 14, 2015 11:31 AM
    dooper55 dooper55 Apr 14, 2015 1:21 PM Flag

    Lengthy Omidria history. Not sure why so much was included.

    OMS721 compassionate use approval in Europe was included, so very up-to-date.

    Quite a few GPCR charts .... more than normal. Maybe something brewing? (Label that wishful thinking until something actually happens.)

  • They're quite different from the usual and are available on their website.
    Try calendar area .... events .....
    Downloadable "Omeros Corporation Corporate Presentation" low on the page

  • European Regulatory Authority Approves Clinical Investigator's Request for Compassionate Use with Omeros Corporation's OMS721

    Date(s): 14-Apr-2015 7:01 AM

    -- Patients with Thrombotic Microangiopathy Will Now Be Able to Receive Extended Treatment -

    SEATTLE, April 14, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that the presiding European regulatory authority has approved the company's investigational product OMS721 for compassionate use. OMS721 is Omeros' lead human monoclonal antibody in its mannan-binding lectin-associated serine protease-2 (MASP-2) program for the treatment of thrombotic microangiopathies (TMAs), including atypical hemolytic uremic syndrome (aHUS). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) in the microcirculation of the body's organs, most commonly the kidney and brain.

    The two patients in the compassionate-use study suffer from aHUS and were enrolled in the first cohort of the Phase 2 clinical trial. Based on improvements across markers of disease activity in that cohort, the investigator requested that Omeros continue to provide OMS721 so that the patients could extend their treatments. Following regulatory approval, Omeros was pleased to release shipment of OMS721 to continue treatment of these patients.

    Omeros' ongoing OMS721 Phase 2 study continues to progress through its dose-ranging phase. The second cohort of patients, which received a higher dose than the first cohort, has now completed treatment. Following a pre-planned data review by internal and external physicians, if the safety data from the second cohort are acceptable, a recommendation will be made to advance as scheduled to a third cohort at an even higher dose. This third cohort could begin dosing before the end of April.

    [more in news release]

  • dooper55 dooper55 Apr 9, 2015 5:04 PM Flag

    Right jbg ......

    SEATTLE, April 9, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 14th Annual Needham Healthcare Conference in New York next week. The presentation is scheduled for Tuesday, April 14 at 10:40am EDT.

    The presentation will be webcast. The live and archived webcasts can be accessed on the "Events" page under the Investors section of the Company's website.

  • dooper55 dooper55 Apr 9, 2015 7:11 AM Flag

    You're totally wrong danzimbabwe.

  • New Alan Ross article on SeekingAlpha

  • Reply to

    upgraded on launch of OMIDRIA

    by stocktraderathome Apr 6, 2015 8:54 AM
    dooper55 dooper55 Apr 6, 2015 11:45 AM Flag

    "Wedbush analyst Liana Moussatos reiterated an Outperform rating and boosted her price target on Omeros Corp. (NASDAQ: OMER) to $61.00 (from $54.00) after the company announced the US commercial launch of OMIDRIA

    Moussatos commented, "We have increased our multiple on peak OMIDRIA sales to 10x from 9x to reflect the reduced risk with commercial launch. We calculate our 12-month price target by projecting present day fair value by 12 months. Our present day fair value is based on a sum-of-parts with each part's value calculated using a 30% annual discount from our net peak annual sales estimate to present day for each product and indication with clinical proof-of-concept for efficacy, then applying a 1-10x multiple depending on stage of development to reflect risk.""

  • Check your news source for this headline ....

    "Seattle biopharmaceutical company Omeros launches first commercial product"

  • dooper55 dooper55 Apr 2, 2015 1:28 PM Flag

    Dr. Donnenfeld is a consultant/advisor to OMER according to Acuity Advisors, LLC, and he is the immediate-past president of the American Society of Cataract and Refractive Surgery, Editor in Chief of Cataract & Refractive Surgery Today and EyeWorld; and Past president of Ocular Microbiology and Immunology Group. Therefore, IMO, his words have a high level of credibility.

  • Zacks: Omeros Receives Average Rating of “Strong Buy” from Analysts (NASDAQ:OMER)

    March 24th, 2015

    Omeros (NASDAQ:OMER) has earned an average broker rating score of 1.20 (Strong Buy) from the five analysts that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a buy rating and four have given a strong buy rating to the company. Omeros’ rating score has improved by 20% from 90 days ago as a result of various analysts’ upgrades and downgrades.

    Analysts have set a 1-year consensus price target of $38.50 for the company and are forecasting that the company will post ($0.66) EPS for the current quarter, according to Zacks. Zacks has also given Omeros an industry rank of 112 out of 265 based on the ratings given to related companies.

  • Good call. Lots of moving parts at OMER. Full national launch of Omidria in early April.

  • Just a reminder. Info down about 8-9 topics.

  • Posted by Reagan on Mar 13th, 2015

    Investment analysts at MLV & Co
    set a $38.00 target price on shares of Omeros (NASDAQ:OMER) stock in a note issued to investors on Friday. The firm currently has a a “buy” rating on the stock. MLV & Co‘s price target suggests a potential upside of 50.73% from the stock’s previous close.

    Omeros (NASDAQ:OMER) traded up 2.81% on Friday, hitting $25.21. 313,561 shares of the company’s stock traded hands. Omeros has a 52-week low of $9.76 and a 52-week high of $27.64. The stock’s 50-day moving average is $22. and its 200-day moving average is $18.. The company’s market cap is $859.03 million.

    A number of other analysts have also recently weighed in on OMER. Analysts at Maxim Group raised their price target on shares of Omeros from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, February 20th. Analysts at Wedbush set a $52.00 price target on shares of Omeros and gave the company a “buy” rating in a research note on Thursday, February 19th. Finally, analysts at Zacks upgraded shares of Omeros from a “neutral” rating to an “outperform” rating and set a $25.40 price target on the stock in a research note on Monday, February 2nd. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Omeros currently has a consensus rating of “Buy” and a consensus price target of $32.90.

    Omeros Corporation operates as a biopharmaceutical company focused on the discovery, development and commercialization of products focused on inflammation and disorders of the central nervous system. The Company develops pharmaceutical and therapeutic approaches to the management of surgical pain and inflammation, vasospasm, smooth muscle spasm, vascular restenosis and implantable surgical devices.

  • SEATTLE, March 9, 2015 /PRNewswire/ -- Omeros Corporation OMER, -4.36% a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that the company will issue its fourth quarter and full-year 2014 financial results for the period ended December 31, 2014, on Monday, March 16, 2015, after market close. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results.

    Conference Call Details
    To access the live conference call via phone, please dial (844) 831-4029 from the United States and Canada or (920) 663-6278 internationally. The participant passcode is 1480892. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available for one week following the call and may be accessed by dialing (855) 859-2056 from the United States and Canada or (404) 537-3406 internationally. The replay passcode is 1480892

  • dooper55 dooper55 Mar 5, 2015 9:37 AM Flag

    From OMER's website.
    ********************************************************************************
    PharmacoSurgery: OMS201

    OMS201 is being developed for use during urological procedures. OMS201 is a proprietary combination of an anti-inflammatory agent and a smooth muscle relaxant. Both active agents are contained in generic, FDA-approved drugs with well-known profiles of safety and pharmacologic activities, and each is contained in drugs that have been marketed in the U.S. for more than 15 years.

    Added to standard irrigation solutions in urological procedures, OMS201 is delivered directly to sites of inflammation or surgical procedures. For example, OMS201 may be used during uroendoscopic procedures, such as bladder endoscopy, minimally invasive prostate surgery and ureteroscopy, to inhibit surgically induced inflammation, pain and smooth muscle spasm.

    (More info on the website)

OMER
24.32-0.35(-1.42%)Apr 24 4:00 PMEDT